

Abemaciclib (methanesulfonate)

Catalog No: tcsc1229



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg



Specifications

CAS No:

1231930-82-7

Formula:

$C_{28}H_{36}F_2N_8O_3S$

Pathway:

Cell Cycle/DNA Damage

Target:

CDK

Purity / Grade:

>98%

Solubility:

H₂O : ≥ 250 mg/mL (414.80 mM)

Alternative Names:

LY2835219 (methanesulfonate)

Observed Molecular Weight:

602.7


Product Description

Abemaciclib (LY2835219) (methanesulfonate) is a selective **CDK4/6** inhibitor with **IC₅₀s** of 2 nM and 10 nM for CDK4 and CDK6, respectively.

IC50 & Target: IC50: 2 nM (CDK4), 10 nM (CDK6)^[3]

In Vitro: Abemaciclib (LY2835219) reduces cell viability with the IC₅₀ values ranging from 0.5 μM to 0.7 μM, inhibits Akt and ERK signaling but not mTOR activation at head and neck squamous cell carcinoma (HNSCC) cells^[1]. Abemaciclib (LY2835219) shows inhibition on A375R1-4, M14R, and SH4R with EC₅₀ values ranging from 0.3 to 0.6 μM; Abemaciclib inhibits the proliferation of the parental A375 and resistant A375RV1 and A375RV2 cells with similar potencies with IC₅₀ values of 395, 260, and 463 nM, respectively^[2]. Abemaciclib (LY2835219) inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells^[3].

In Vivo: Abemaciclib (LY2835219) (45 mg/kg, p.o.) in combination with everolimus causes a cooperative antitumor effect in HNSCC xenograft tumor^[1]. Abemaciclib (LY2835219) (45 or 90 mg/kg, p.o.) shows significant tumor growth inhibition in an A375 xenograft model^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!